AOD-9604 Compounding Legal Status: What Patients and Prescribers Need to Know

What Exactly Is AOD-9604?

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to the C-terminal fragment (residues 176 through 191) of human growth hormone, with an added tyrosine residue at the N-terminus. The abbreviation "AOD" stands for Anti-Obesity Drug, reflecting its original development intent. Metabolic Pharmaceuticals Pty Ltd, an Australian biotechnology company, developed the compound in the 1990s specifically to isolate the lipolytic activity of growth hormone while avoiding the diabetogenic and mitogenic effects associated with full-length recombinant hGH.

Mechanism of Action

The peptide does not bind the classical growth hormone receptor with meaningful affinity. Instead, AOD-9604 appears to interact with beta-3 adrenergic receptors in adipose tissue, triggering intracellular signaling that promotes fat breakdown. Heffernan et al. (2001) demonstrated in a rodent model that the fragment stimulated lipolysis and inhibited lipogenesis at doses far below those required for full-length hGH, without producing detectable changes in serum IGF-1 or causing cartilage proliferation. [1]

What AOD-9604 Is Not

It is not somatropin, sermorelin, or any GHRH analog. It carries no recognized anabolic or insulin-sensitizing activity at the doses studied in humans. This distinction matters for regulatory classification because peptides that qualify as growth hormone analogs face stricter scheduling under the Anabolic Steroid Control Act, and AOD-9604 does not meet that structural threshold.

FDA Regulatory Classification of AOD-9604

AOD-9604 is an unapproved new drug under 21 U.S.C. § 321(p). The FDA has not approved a New Drug Application (NDA), Biologics License Application (BLA), or Abbreviated New Drug Application (ANDA) for any product containing AOD-9604. A search of the FDA's Drugs@FDA database returns zero approved applications for this active ingredient as of January 2025.

The GRAS Self-Affirmation Path

Metabolic Pharmaceuticals did file for Generally Recognized as Safe (GRAS) status with the FDA in 2004, seeking to use AOD-9604 as a functional food ingredient for obesity management. The FDA acknowledged the submission (GRN 000184) but never issued a "no questions" letter. The agency's response indicated that the available data did not adequately support the GRAS determination for intended human food use. That administrative outcome is sometimes misrepresented online as "FDA approval." It is not. A GRAS acknowledgment for food ingredient status is categorically different from drug approval.

IND and Clinical Trial History

An Investigational New Drug (IND) application supported the clinical development program. Metabolic Pharmaceuticals completed Phase 2b trials in humans for obesity indications. A 12-week randomized controlled trial (N=300 approximately) published in conjunction with the development program showed statistically significant fat mass reduction with oral AOD-9604 1 mg/day versus placebo, with a P<0.05 threshold met for body weight change in the per-protocol population. [2] However, Metabolic Pharmaceuticals never filed a Phase 3 package with the FDA for drug approval, and the company's obesity program was discontinued around 2007.

The IND process conferred no approved-drug status. Conducting clinical trials under an IND simply means the FDA allowed the research to proceed. It does not authorize commercial distribution or compounding for general patient populations.

503A and 503B Compounding Eligibility

This is the core regulatory issue for any U.S. Telehealth company or compounding pharmacy. Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 353a, 353b), a compounding pharmacy may prepare a drug containing a bulk substance only under specific, narrowly defined conditions.

The 503A Bulk Substance Framework

For 503A traditional compounding pharmacies, a bulk substance used in compounding must either:

• Appear on the FDA's 503A bulk substance list (the "Category 1" list of nominated substances evaluated for safety and clinical need), or
• Be a component of an FDA-approved drug, or
• Comply with an applicable United States Pharmacopeia (USP) monograph.

AOD-9604 does not meet any of these criteria. The substance was nominally submitted for consideration in past FDA docket cycles, but it has not been placed on the Category 1 approved list. The FDA's Center for Drug Evaluation and Research (CDER) has instead classified AOD-9604 among substances that raise safety or effectiveness concerns that preclude their inclusion in routine compounding. [3]

The 503B Outsourcing Facility Framework

503B outsourcing facilities operate under even stricter rules. They may compound drugs only from bulk substances that appear on the FDA's 503B bulk substance list or from components of approved drugs. AOD-9604 does not appear on the 503B bulk substance list. Period.

What This Means in Practice

A 503A pharmacy that compounds and dispenses AOD-9604 based on a patient-specific prescription is dispensing an unapproved new drug. Unless the FDA has issued specific enforcement discretion (it has not for AOD-9604 as of this writing), that pharmacy is operating outside the law. A prescriber writing that prescription may be facilitating the distribution of an unapproved new drug, which carries its own professional and legal exposure.

The HealthRX Medical Team applies a three-question framework before any peptide is considered for a patient referral to a compounding pharmacy:

1. Does the substance appear on the current FDA 503A Category 1 bulk substance list?
2. Is there at least one adequately powered Phase 3 randomized controlled trial with published safety data beyond 24 weeks?
3. Has the FDA issued any formal enforcement discretion or guidance specifically permitting compounding of this substance?

AOD-9604 fails all three questions as of January 2025.

FDA Enforcement Actions Against Peptide Compounders

The FDA has escalated scrutiny of compounding pharmacies offering unapproved peptides. In November 2022 and again in 2023, the FDA issued warning letters to multiple 503A facilities citing violations that included the compounding of bulk drug substances not appearing on any approved list. While the publicly available warning letters available via FDA's warning letter database do not all name AOD-9604 explicitly, several address the broader category of unapproved peptide fragments. [4]

The BPC-157 and Ipamorelin Precedent

AOD-9604 is not the only peptide in this position. BPC-157, ipamorelin, CJC-1295, and TB-500 have all been the subject of FDA action letters or import alerts. Each was once widely compounded and prescribed through telehealth channels before the FDA moved to restrict them. The regulatory trajectory for these peptides provides a clear pattern: the agency tolerates informal practice for a period, then issues guidance classifying the substance as ineligible for compounding, followed by warning letters and, in some cases, criminal referrals to the Department of Justice.

Melanotan II as a Cautionary Case

Melanotan II, a synthetic melanocortin analog that was similarly never approved, was widely compounded until coordinated FDA and DEA action in 2020 and 2021 effectively ended its commercial availability through legitimate compounding channels. Prescribers who had built practices around that compound found themselves exposed retroactively. The parallels to AOD-9604's current situation are direct.

Available Human Safety Data

The absence of FDA approval does not automatically mean a compound is unsafe. It means the available evidence has not met the agency's threshold for a risk-benefit determination. For AOD-9604, the honest clinical picture is one of limited but broadly reassuring short-term data, with meaningful gaps beyond 12 weeks.

Phase 2 Human Trial Safety Findings

The Metabolic Pharmaceuticals Phase 2 program included several hundred subjects across multiple dose-ranging studies. Adverse event profiles at oral doses of 1 mg/day and subcutaneous doses up to 500 mcg/day showed predominantly mild injection site reactions (erythema, transient induration) and occasional headache. [2] No serious adverse events attributed to the study drug were reported in the published summaries of these trials. No elevations in fasting glucose, no suppression of endogenous GH secretion, and no IGF-1 changes were documented at therapeutic doses.

What the Animal Data Showed

Heffernan et al. (2001) demonstrated in obese Zucker rats that AOD-9604 reduced body weight gain by approximately 50% over a six-week treatment period compared to saline controls, at a dose of 500 mcg/kg/day subcutaneously, without affecting IGF-1 levels or causing organ toxicity on necropsy. [1] Rodent data do not translate directly to human outcomes, and no carcinogenicity study of adequate duration in two species has been submitted to the FDA.

Long-Term Safety Gaps

No published study has followed human subjects receiving AOD-9604 beyond 12 weeks. No data exist on effects during pregnancy (FDA Pregnancy Category not assigned; no animal reproductive toxicology studies are publicly available for this fragment specifically). The compounded injectable form introduces sterility and endotoxin risks that oral research formulations did not carry. Subcutaneous injection also raises questions about local depot accumulation that have not been studied.

Current Prescribing Environment and Telehealth Risk

Despite the unfavorable regulatory picture, AOD-9604 remains widely marketed by some telehealth platforms and compounding pharmacies as a "fat loss peptide." This has continued partly because the FDA's enforcement resources are finite and the agency's primary focus from 2022 through 2024 has been on semaglutide and tirzepatide compounding issues related to drug shortages. That enforcement prioritization should not be read as FDA tolerance of AOD-9604 compounding.

What Prescribers Should Document

A prescriber who, after reviewing this regulatory context, still believes a specific patient has a compelling clinical need may wish to document:

• A detailed off-label prescribing rationale in the patient's chart
• Informed consent that explicitly states AOD-9604 is not FDA-approved, has not completed a Phase 3 program, and is being compounded outside the 503A bulk substance list
• The name, PCAB accreditation status, and 503A registration of the compounding pharmacy
• A plan for monitoring and a defined treatment duration with objective endpoints

Doing so does not make the prescription legal under FDA regulations, but it does reflect a standard of care that would be evaluated in any subsequent disciplinary or malpractice proceeding.

State Pharmacy Board Variation

State pharmacy boards regulate compounding pharmacies within their jurisdictions and vary considerably in their interpretation of permissible bulk substances. Several states, including Florida and Texas, have historically been more permissive. However, FDA inspections of 503A pharmacies are not constrained by state-level permissiveness. A pharmacy that is in compliance with Florida Board of Pharmacy rules can still receive an FDA warning letter and face federal injunction if it dispenses a substance the FDA classifies as ineligible for compounding. [4]

How AOD-9604 Compares to Approved Alternatives

Patients typically seeking AOD-9604 are looking for a peptide that supports fat loss without the adverse metabolic profile of full-length hGH. Several alternatives either hold FDA approval or occupy a clearer regulatory position.

Semaglutide (Wegovy) and Tirzepatide (Zepbound)

Both semaglutide 2.4 mg (Wegovy) and tirzepatide 15 mg (Zepbound) are FDA-approved for chronic weight management. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001). [5] In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks (P<0.001). [6] Neither is a peptide in the traditional compounding sense, but both are available through legitimate prescribing channels with strong safety databases.

Tesamorelin (Egrifta)

Tesamorelin, a GHRH analog, holds FDA approval specifically for HIV-associated lipodystrophy. Its use for general fat loss in non-HIV patients is off-label, but the compound itself is an approved drug and can be prescribed as such. This is a categorically different legal position from AOD-9604.

Sermorelin

Sermorelin was an FDA-approved drug (as Geref) that was voluntarily withdrawn from the market by the manufacturer in 2008. Because sermorelin was once a component of an FDA-approved product, it occupies a more defensible position under the 503A framework than AOD-9604, though compounders must still manage timeliness and clinical necessity requirements.

Practical Guidance for Patients Asking About AOD-9604

Patients frequently arrive at telehealth consultations having read marketing materials that describe AOD-9604 as "FDA-cleared" or "GRAS-approved." Neither phrase accurately describes the compound's status.

The FDA's 2023 guidance on bulk drug substances for 503A compounding makes the regulatory framework transparent to anyone willing to read it. [3] The guidance document states directly: "A bulk drug substance nominated for the 503A bulks list that FDA has not evaluated or placed on the list... Cannot be used as a bulk drug substance in compounding."

Patients should ask any provider offering AOD-9604 three direct questions:

1. Is this substance on the FDA's 503A bulk substance Category 1 list?
2. Can you provide the pharmacy's current 503A registration and PCAB accreditation documents?
3. What is your documented protocol if I experience an adverse event?

A provider who cannot answer all three clearly is not adequately informed about the regulatory and safety context of what they are prescribing.

The Path to Legitimacy for AOD-9604

AOD-9604 is not irredeemably barred from U.S. Patient access. A plausible path exists. A sponsor could file a new IND, conduct a properly powered Phase 3 randomized controlled trial for a defined obesity or metabolic indication, and submit an NDA to the FDA. The existing Phase 2 data, while modest in scale, provide a starting dose and safety signal that would inform such a trial design. Separately, a compounding interest group could nominate AOD-9604 for the 503A bulk substance list with a comprehensive safety and clinical-need dossier. The FDA is obligated to evaluate such nominations. Whether the current evidence base would satisfy CDER reviewers is uncertain, but the pathway exists.

Until one of those routes produces a formal regulatory determination, AOD-9604 compounding remains legally unsupported in the United States.